The zanidatamab-plus-chemotherapy arm met its overall survival end point at the second interim analysis of the phase 3 HERIZON-GEA-01 trial.
|Videos|April 26, 2016
Dr. Geschwind on Locoregional Therapy for Patients With Liver Cancer
Author(s)Jeff Geschwind, MD
Jeff Geschwind, MD, professor and chairman, Radiology and Biomedical Imaging, Yale Cancer Center, discusses locoregional treatment options for patients with hepatocellular carcinoma (HCC).
Advertisement
Jeff Geschwind, MD, professor and chairman, Radiology and Biomedical Imaging, Yale Cancer Center, discusses locoregional treatment options for patients with hepatocellular carcinoma (HCC).
Regardless of whether a patient has localized or metastatic HCC, practitioners are able to deliver treatment to patients through the hepatic artery. Such therapies include chemotherapy and radiation therapy in order to maximize the potency but minimize toxicities.
<<<
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover pancreatic cancer, gastric cancer, GIST, renal cell carcinoma, and chronic lymphocytic leukemia.
The FDA approved daraxonrasib for pancreatic cancer, cleared zanidatamab-based regimens for HER2-positive gastric cancer, and more.
Patient-reported QOL and symptom outcomes were similar between belzutifan plus lenvatinib and cabozantinib in previously treated RCC.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The conditional approval of fanregratinib is supported by pivotal phase 2 data showing a 42.5% objective response rate in pretreated FGFR2-altered intrahepatic cholangiocarcinoma.
The FDA approval of daraxonrasib was based on data from the phase 3 RASolute 302 trial in previously treated metastatic pancreatic ductal adenocarcinoma.
Ivonescimab plus chemotherapy significantly improved overall survival vs durvalumab plus chemotherapy in advanced biliary tract cancer.
Advertisement
Advertisement
Trending on OncLive
1
European Commission Approves T-DXd Plus Pertuzumab for First-Line HER2+ Metastatic Breast Cancer
2
Dr Huffman on the Mechanism of Action of INCB161734 in KRAS G12D–Mutated Metastatic Pancreatic Cancer
3
ASPEN-09-03 Trial Aims to Build the Case for Evorpacept in Post–T-DXd HER2+ Breast Cancer
4
MAPKeeper-301 Aims to Confirm the Efficacy of Atebimetinib in Metastatic Pancreatic Cancer
5